1. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to
a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to
moderate renal impairment: a post hoc analysis. Clin Ther 2003; 25:2754-64.
2. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of
metformin and rosiglitazone, alone and in combination, in nonobese women with
polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril
2004; 82:893-902.
3. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1
lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;
363:429-38.
4. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized,
placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis
2007; 195:1754-61.
5. Coll B, van Wijk JP, Parra S, et al. Effects of rosiglitazone and metformin on
postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human
immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006;
544:104-10.
6. Dailey GE, III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with
glyburide/metformin tablets in combination with rosiglitazone in patients with type 2
diabetes: a randomized, double-blind trial. Am J Med 2004; 116:223-9.
7. (a) Derosa G, Gaddi AV, Ciccarelli L, et al. Long-term effect of glimepiride and
rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated
patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J
Int Med Res 2005; 33:284-94.
8. (b) Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and
rosiglitazone in patients with diabetes and metabolic syndrome treated with
1
glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled,
parallel-group trial. Clin Ther 2004; 26:744-54.
9. (c) Derosa G, Cicero AF, D'Angelo A, et al. Effects of 1 year of treatment with
pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and
homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic
syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther
2006; 28:679-88.
10. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide
versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately
controlled on metformin monotherapy. Diabetes Obes Metab 2006; 8:15663.Goldberg
11. Jung HS, Youn BS, Cho YM, et al. The effects of rosiglitazone and metformin on
the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Metabolism 2005; 54:314-20.
12. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone
improves endothelial function and inflammation but not asymmetric dimethylarginine
or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007; 12:3118.
13. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime
insulin in the treatment of patients with conventional oral antidiabetic drug failure: a
1-year randomized clinical trial. Adv Ther 2006; 23:799-808.
14. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl
estradiol/cyproterone acetate as single and combined treatment of overweight
women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006;
21:121-8.
2
15. Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after
coronary stenting in patients with type 2 diabetes. Am Heart J 2004; 147:e23.
16. Rahman S, Ismail AA, Ismail SB, Naing NN, bdul Rahman AR. Effect of
rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated
diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled
study. Eur J Clin Pharmacol 2007; 63:733-41.
17. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of
rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and
lipids in type 2 diabetes. Diabetes Res Clin Pract 2007; 77:180-7.
18. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome
proliferator-activated receptor-gamma agonist, on markers of endothelial cell
activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery
disease patients. J Am Coll Cardiol 2003; 42:1757-63.
19. Silic A, Janez A, Tomazic J, et al. Effect of rosiglitazone and metformin on insulin
resistance in patients infected with human immunodeficiency virus receiving highly
active antiretroviral therapy containing protease inhibitor: randomized prospective
controlled clinical trial. Croat Med J 2007; 48:791-9.
20. van Wijk JP, de Koning EJ, Castro CM, Rabelink TJ. Rosiglitazone improves
postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes
Care 2005; 28:844-9.
21. Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X. Peroxisome proliferator-activated
receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in
type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism
2005; 54:590-7.
3
22. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to
submaximal doses of metformin compared with dose escalation of metformin in type
2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005; 21:2029-35.
23. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces
insulin requirement and C-reactive protein levels in type 2 diabetic patients
receiving (3)peritoneal dialysis. Am J Kidney Dis 2005; 46:713-9.
24. Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet
beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes
Metab Res Rev 2005; 21:203-8.
4